State University of New York at Buffalo
This study will examine the effects of 24 weeks of lithium therapy achieving serum lithium levels of 0.25-0.50mmol/L on MRI and blood-based biomarkers in Parkinson's disease patients who have completed one of our current 24-week lithium clinical trials.
In observational studies, small daily doses of lithium from smoking cigarettes have been associated with a 77% reduced risk of developing Parkinson's disease (PD). In addition, lithium therapy has been effective in preventing neuronal death and behavioral symptoms in several PD animal models. Recently, our group has shown 24-weeks of low-dose lithium therapy in PD to be associated with improvements in both MRI and blood-based biomarkers implying that lithium may be slowing the progression of the disease. However, these findings stemmed from only three of four patients receiving MRIs. Our group…
1. All PD patients completing STUDY00007253 or STUDY00008239 at the University at Buffalo will be eligible. 2. No unstable cardiac, medical, neurologic or psychiatric condition in the opinion of the PI. 3. No current use of illicit drugs or current alcohol abuse in the opinion of the PI. 4. No history of brain surgery or possible need for brain surgery including deep brain stimulation (DBS) for at least 24 weeks in the opinion of the PI. 5. Women with child bearing potential will need a negative pregnancy test and not be nursing an infant at screening. Women with child bearing potential will n…
Lithium aspartate with dosage adjusted to serum lithium level 0.25-0.50mmol/L
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.